Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caroverine SCHEMBL31128388 | 1.00 | DRD3 (1.00) | DRD3MLNRADORA3ADRA2BADRA2C | |
| Caroverine SCHEMBL2258789 | 0.99 | DRD3 (0.98) | DRD3MLNRADORA3ADRA2BADRA2C | |
| Caroverine SCHEMBL1649725 | 0.98 | DRD3 (0.96) | DRD3MLNRADORA3ADRA2BADRA2C | |
| Caroverine SCHEMBL28086487 | 0.94 | DRD3 (0.89) | DRD3MLNRADORA3ADRA2BADRA2C | |
| Caroverine SCHEMBL7279211 | 0.92 | DRD3 (0.85) | DRD3MLNRADORA3ADRA2BADRA2C | |
| Caroverine SCHEMBL11330670 | 0.87 | DRD3 (0.76) | DRD3MLNRADORA3ADRA2BADRA2C | |
| SCHEMBL3881848 | 0.87 | MLNR (0.77) | DRD3MLNRADORA3ADRA2BADRA2C | |
| SCHEMBL3900890 | 0.79 | PDE4D (0.65) | DRD3MLNRADORA3ADRA2BADRA2C | |
| SCHEMBL3881842 | 0.77 | MLNR (0.62) | DRD3MLNRADORA3ADRA2BADRA2C | |
| SCHEMBL982499 | 0.74 | MAPK1 (0.75) | DRD3MLNRADORA3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1763 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152568-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. | 2025-05-15 | — | — | US | claimed |
| EP-4475887-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | Aisa Pharma, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024211216-A1 | CILNIDIPINE AND A P-GLYCOPROTEIN INHIBITOR FOR TREATING PAIN | AISA PHARMA, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2023150336-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| US-10695168-B2 | Prosthetic devices for semicircular canal defects | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-06-30 | — | — | US | claimed |
| US-20190125679-A1 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2019-05-02 | — | — | US | claimed |
| EP-3373943-A1 | CONTROL OF CELLULAR REDOX LEVELS | Mckenna, Elizabeth (US) | 2018-09-19 | — | — | EP | claimed |
| CN-108430482-A | Control of cellular redox levels | 伊丽莎白·麦克纳 | 2018-08-21 | — | — | CN | claimed |
| EP-2956450-B1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | UNIV MUENCHEN TECH (DE) | 2018-07-25 | — | — | EP | claimed |
| US-20050288292-A1 | Pharmaceutical formulation and its use in the treatment of inner ear diseases | PHAFAG AG (LI) | 2005-12-29 | — | — | US | claimed |
| CN-1379686-A | Composition comprising tramadol material and anticonvulsant drug | ORTHO MCNEIL PHARM INC (US) | 2002-11-13 | — | — | CN | claimed |
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | PHAFAG AKTIENGESELLSCHAFT (LI) | 2001-07-05 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-0542689-B1 | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions | PHAFAG AG (LI) | 1998-09-23 | — | — | EP | claimed |
| US-5563140-A | Use of 1-(aminoalkyl)-3-(benzyl)-quinoxaline-2-one derivatives for the preparation of neuroprotective compositions | PHAFAG AKTIENGESELLSCHAFT (LI) | 1996-10-08 | — | — | US | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0542689-A1 | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions | PHAFAG AKTIENGESELLSCHAFT (LI) | 1993-05-19 | — | — | EP | claimed |
| WO-1992016226-A1 | IL-1 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | GLS, GLUL, GLS2 | DRD3 928/4885MLNR 1977/4885ADORA3 705/4885 |
| US-20050288292-A1 | Pharmaceutical formulation and its use in the treatment of inner ear diseases | SLC26A4, TIMM10, AQP1 | DRD3 3212/4885MLNR 3939/4885ADORA3 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.